T. Rowe Price Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $337M | Buy |
|
|||||
|
2025
Q1 | $353M | Sell |
|
|||||
|
2024
Q4 | $426M | Sell |
|
|||||
|
2024
Q3 | $1.05B | Buy |
|
|||||
|
2024
Q2 | $635M | Buy |
|
|||||
|
2024
Q1 | $680M | Buy |
|
|||||
|
2023
Q4 | $364M | Buy |
|
|||||
|
2023
Q3 | $388M | Buy |
|
|||||
|
2023
Q2 | $392M | Sell |
|
|||||
|
2023
Q1 | $486M | Sell |
|
|||||
|
2022
Q4 | $532M | Buy |
|
|||||
|
2022
Q3 | $433M | Sell |
|
|||||
|
2022
Q2 | $1.12B | Sell |
|
|||||
|
2022
Q1 | $1.15B | Buy |
|
|||||
|
2021
Q4 | $209M | Sell |
|
|||||
|
2021
Q3 | $231M | Buy |
|
|||||
|
2021
Q2 | $239M | Sell |
|
|||||
|
2021
Q1 | $229M | Sell |
|
|||||
|
2020
Q4 | $244M | Sell |
|
|||||
|
2020
Q3 | $415M | Sell |
|
|||||
|
2020
Q2 | $508M | Sell |
|
|||||
|
2020
Q1 | $540M | Sell |
|
|||||
|
2019
Q4 | $717M | Sell |
|
|||||
|
2019
Q3 | $684M | Buy |
|
|||||
|
2019
Q2 | $578M | Buy |
|
|||||
|
2019
Q1 | $426M | Buy |
|
|||||
|
2018
Q4 | $413M | Sell |
|
|||||
|
2018
Q3 | $694M | Buy |
|
|||||
|
2018
Q2 | $587M | Sell |
|
|||||
|
2018
Q1 | $687M | Sell |
|
|||||
|
2017
Q4 | $748M | Sell |
|
|||||
|
2017
Q3 | $823M | Sell |
|
|||||
|
2017
Q2 | $751M | Sell |
|
|||||
|
2017
Q1 | $1.28B | Sell |
|
|||||
|
2016
Q4 | $2.16B | Sell |
|
|||||
|
2016
Q3 | $2.43B | Sell |
|
|||||
|
2016
Q2 | $5.31B | Buy |
|
|||||
|
2016
Q1 | $4.17B | Buy |
|
|||||
|
2015
Q4 | $3.36B | Buy |
|
|||||
|
2015
Q3 | $2.48B | Buy |
|
|||||
|
2015
Q2 | $2.23B | Buy |
|
|||||
|
2015
Q1 | $929M | Sell |
|
|||||
|
2014
Q4 | $897M | Sell |
|
|||||
|
2014
Q3 | $791M | Sell |
|
|||||
|
2014
Q2 | $812M | Sell |
|
|||||
|
2014
Q1 | $917M | Buy |
|
|||||
|
2013
Q4 | $790M | Buy |
|
|||||
|
2013
Q3 | $654M | Buy |
|
|||||
|
2013
Q2 | $631M | Buy |
|